Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNam Su Kuen_US
dc.contributor.authorAwachana Jiamsakulen_US
dc.contributor.authorOon Tek Ngen_US
dc.contributor.authorEvy Yunihastutien_US
dc.contributor.authorDo Duy Cuongen_US
dc.contributor.authorMan Po Leeen_US
dc.contributor.authorBenedict Lim Heng Simen_US
dc.contributor.authorPraphan Phanuphaken_US
dc.contributor.authorWing Wai Wongen_US
dc.contributor.authorAdeeba Kamarulzamanen_US
dc.contributor.authorFujie Zhangen_US
dc.contributor.authorSanjay Pujarien_US
dc.contributor.authorRomanee Chaiwarithen_US
dc.contributor.authorShinichi Okaen_US
dc.contributor.authorMahiran Mustafaen_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorKinh Van Nguyenen_US
dc.contributor.authorRossana Ditangcoen_US
dc.contributor.authorSasisopin Kiertiburanakulen_US
dc.contributor.authorTuti Parwati Meratien_US
dc.contributor.authorNicolas Durieren_US
dc.contributor.authorJun Yong Choien_US
dc.description.abstractCopyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. Elevated CD8 counts with combination antiretroviral therapy (cART) initiation may be an early warning indicator for future treatment failure. Thus, we investigated whether elevated CD8 counts were associated with virological failure (VF) in the first 4 years of cART in Asian HIV-infected patients in a multicenter regional cohort. We included patients from the TREAT Asia HIV Observational Database (TAHOD). Patients were included in the analysis if they started cART between 1996 and 2013 with at least one CD8 measurement within 6 months prior to cART initiation and at least one CD8 and viral load (VL) measurement beyond 6 months after starting cART. We defined VF as VL ≥400 copies/mL after 6 months on cART. Elevated CD8 was defined as CD8 ≥1200 cells/μL. Time to VF was modeled using Cox regression analysis, stratified by site. In total, 2475 patients from 19 sites were included in this analysis, of whom 665 (27%) experienced VF in the first 4 years of cART. The overall rate of VF was 12.95 per 100 person-years. In the multivariate model, the most recent elevated CD8 was significantly associated with a greater hazard of VF (HR = 1.35, 95% CI 1.14-1.61; P = 0.001). However, the sensitivity analysis showed that time-lagged CD8 measured at least 6 months prior to our virological endpoint was not statistically significant (P = 0.420). This study indicates that the relationship between the most recent CD8 count and VF was possibly due to the CD8 cells reacting to the increase in VL rather than causing the VL increase itself. However, CD8 levels may be a useful indicator for VF in HIV-infected patients after starting cART.en_US
dc.titleElevated CD8 T-cell counts and virological failure in HIV-infected patients after combination antiretroviral therapyen_US
article.title.sourcetitleMedicine (United States)en_US
article.volume95en_US University College of Medicineen_US of New South Wales (UNSW) Australiaen_US Tock Seng Hospitalen_US of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US Mai Hospitalen_US Elizabeth Hospital Hong Kongen_US Sungai Bulohen_US HIV Netherlands Australia Thailand Research Collaborationen_US General Hospital-Taipeien_US of Malaya Medical Centreen_US Medical University Chinaen_US of Infectious Diseasesen_US Mai Universityen_US Center for Global Health and Medicineen_US Raja Perempuan Zainab IIen_US Medical Centre Indiaen_US Hospital for Tropical Diseasesen_US Universityen_US Udayanaen_US - The Foundation for AIDS Researchen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.